Data S1. Evaluation of Fluoxetine in Overall Survival of GBM Patients Using Electronic Medical Records from The IBM MarketScan Dataset

The potential therapeutic benefit of fluoxetine with standard of care treatment was evaluated in GBM patients cohort using electronic medical records from the IBM MarketScan Dataset (2003-2017). GBM Patients with two other SSRIs, citalopram and escitalopram, were used as controls. The dataset includes six figures: data S1 Figures 1-6 which provide more details of the data overview, data extraction pipeline, exclusion criteria, enrichment for GBM patients, statistical analyses, and results.

本研究依托IBM MarketScan数据集（2003-2017年）收录的电子病历，针对胶质母细胞瘤（GBM）患者队列，评估了氟西汀联合标准治疗方案的潜在治疗获益。本研究选取同时使用另外两种选择性5-羟色胺再摄取抑制剂（SSRIs）——西酞普兰（citalopram）与艾司西酞普兰（escitalopram）的GBM患者作为对照队列。该数据集包含六幅附图：数据补充材料S1中的图1至图6，分别详细展示了数据概况、数据提取流程、排除标准、GBM患者富集策略、统计分析方法及研究结果。